As of Apr 28
| +5.20 / +4.32%|
The 13 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 116.00, with a high estimate of 229.00 and a low estimate of 93.00. The median estimate represents a -7.72% decrease from the last price of 125.70.
The current consensus among 14 polled investment analysts is to Hold stock in United Therapeutics Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.